Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity

Clinical Pharmacology and Therapeutics
V HafnerGerd Mikus

Abstract

We aimed to assess the effect of coadministration and withdrawal of a potent cytochrome P450 3A (CYP3A) inhibitor (ritonavir) and a potent CYP3A inducer (St John's wort) on CYP3A enzyme activity in an open, fixed-sequence study design. We investigated the pharmacokinetics of midazolam: (i) at baseline, (ii) after a single dose of either St John's wort or ritonavir (each n = 6), (iii) after 14 days of coadministration of ritonavir (300 mg b.i.d.) and St John's wort (300 mg t.i.d.), and (iv) at 2 days after cessation of both St John's wort and ritonavir. Combined administration of inducer and inhibitor resulted in a predominance of enzyme inhibition: coadministration of St John's wort and ritonavir with intravenous administration of midazolam resulted in an increase in the area under the plasma concentration-time curve (AUC)(0-8 h) of midazolam to 180% of baseline value, whereas with orally administered midazolam, the AUC(0-6 h) increased to 412% of baseline value (P < 0.05 for each). After cessation of the coadministered drugs, the AUC(0-6 h) of orally administered midazolam decreased to 6% of the level observed during combined administration, and the AUC(0-8 h) of intravenously administered midazolam decreased to 33% of the val...Continue Reading

References

Aug 1, 1993·Clinical Pharmacology and Therapeutics·R ZandJ M Wright
Jan 1, 1996·European Journal of Clinical Pharmacology·W HimmelM M Kochen
Oct 1, 1996·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M F FrommM Eichelbaum
Sep 5, 1998·Clinical Pharmacology and Therapeutics·I LeclercqY Horsmans
Nov 13, 1998·Clinical Pharmacokinetics·A HsuR J Bertz
Feb 22, 2000·Lancet·F RuschitzkaG Noll
Aug 10, 2000·Journal of Acquired Immune Deficiency Syndromes : JAIDS·D J GreenblattR I Shader
Aug 22, 2000·European Journal of Clinical Pharmacology·L L von MoltkeD J Greenblatt
Dec 24, 2002·Clinical Pharmacology and Therapeutics·Jang-Ik LeeReginald F Frye
Jan 25, 2003·Clinical Pharmacology and Therapeutics·George K DresserRichard B Kim
Mar 19, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ajay MadanAndrew Parkinson
May 7, 2003·Clinical Pharmacology and Therapeutics·Carla B WashingtonUNKNOWN AIDS Clinical Trials Group Protocol (ACTG 378) Study Team
Sep 18, 2003·JAMA : the Journal of the American Medical Association·John S MarkowitzKenneth D Chavin
Jun 8, 2004·International Journal of Clinical Pharmacology and Therapeutics·W HimmelE Hummers-Pradier
Jul 14, 2004·JAMA : the Journal of the American Medical Association·Patrick G YeniPaul A Volberding
Oct 8, 2004·Clinical Pharmacology and Therapeutics·Ingrid MaiIvar Roots
Nov 4, 2004·The Journal of Pharmacology and Experimental Therapeutics·C Steven ErnestDavid R Jones
Nov 13, 2004·Rapid Communications in Mass Spectrometry : RCM·Oscar QuintelaManuel López-Rivadulla
Mar 15, 2005·Clinical Pharmacokinetics·Shufeng ZhouHoward L McLeod
Jul 9, 2005·Clinical Pharmacology and Therapeutics·Jens RengelshausenGerd Mikus
Mar 4, 2006·Clinical Pharmacology and Therapeutics·Kerry E Culm-MerdekDavid J Greenblatt
Oct 3, 2006·British Journal of Clinical Pharmacology·D L WhittenH Wohlmuth
Feb 26, 2008·British Journal of Clinical Pharmacology·Hiromitsu ImaiKyoichi Ohashi
Jun 4, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Odette A FahmiLarry M Tremaine

❮ Previous
Next ❯

Citations

Aug 26, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Laiyou WangXiaochao Ma
Jun 4, 2015·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Andrew StolbachPaul Pham
May 4, 2016·The Journal of Antimicrobial Chemotherapy·Nicolas HohmannWalter E Haefeli
Oct 8, 2016·Expert Review of Clinical Pharmacology·Kristina M BrooksParag Kumar
Oct 8, 2014·Basic & Clinical Pharmacology & Toxicology·Christoph MarkertWalter Emil Haefeli
Mar 5, 2014·Journal of Agricultural and Food Chemistry·Kevin D WelchDaniel Cook
Nov 29, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Dirk TheileJohanna Weiss
Jan 13, 2012·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·Angelo A Izzo
Jun 8, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Aleksandra Kotlinska-Lemieszek
Aug 5, 2015·Journal of Clinical Pharmacology·David J Greenblatt
Feb 4, 2010·Der Internist·V HafnerW E Haefeli
Aug 4, 2010·European Journal of Clinical Pharmacology·Stephanie KatzenmaierGerd Mikus
Dec 15, 2010·Clinical Pharmacokinetics·Thomas N KakudaRichard M W Hoetelmans
Sep 13, 2012·European Journal of Clinical Pharmacology·Ines FuchsGerd Mikus
Jan 20, 2012·Clinical Pharmacokinetics·Shaojun Shi, Ulrich Klotz
Mar 15, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Anja KeublerJürgen Burhenne
Aug 11, 2020·Journal of Pharmacokinetics and Pharmacodynamics·Sabrina T WiebeGerd Mikus
Dec 15, 2010·Journal of Clinical Pharmacology·Leonie FetznerWalter Emil Haefeli
Jan 16, 2015·British Journal of Clinical Pharmacology·Nicolas HohmannGerd Mikus
Jun 12, 2013·European Journal of Clinical Pharmacology·Christine EichbaumGerd Mikus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.